Radioisotopic implantation for carcinoma of the prostate: does it work better than it used to?

Transperineal interstitial permanent prostate brachytherapy is being selected as the treatment of choice for early-stage prostatic carcinoma with increasing frequency by both patients and medical practitioners. This trend is surprising to many who are aware of the disappointing results following the retropubic technique of a few decades ago. Others advocate that the newer techniques, which use technologically advanced imaging of the prostate and sophisticated treatment planning systems, allow highly conformal source placement within the gland, resulting in a dose distribution that is superior to that previously achieved. Does improved dose distribution correlate with a higher local control rates in prostate implant patients? This review compares the historical technique of open laparotomy and retropubic implantation as practiced at Memorial Sloan-Kettering Cancer Center in the 1970s to the contemporary technique of transperineal ultrasound-guided permanent seed placement of the 1990s. The results to date show that the present techniques are producing substantially better outcomes, probably resulting from better patient selection as well as improved dose delivery. This is a US government work. There are no restrictions on its use.

[1]  B W Corn,et al.  Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. , 1997, International journal of radiation oncology, biology, physics.

[2]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[3]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ultrasound guided placement of transperineal prostatic afterloading catheters. , 1994, International journal of radiation oncology, biology, physics.

[5]  W. Whitmore,et al.  Retropubic implantation to iodine 125 in the treatment of prostatic cancer. , 1972, The Journal of urology.

[6]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[7]  C C Ling,et al.  A CT-based evaluation method for permanent implants: application to prostate. , 1993, International journal of radiation oncology, biology, physics.

[8]  K. Wallner Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. , 1991, Oncology.

[9]  J. Montie,et al.  Carcinoma of the prostate: treatment with pelvic lymphadenectomy and iodine-125 implants. , 1979, Clinical bulletin.

[10]  T. Buchholz,et al.  2097 A dose-volume analysis of permanent transperineal prostate brachytherapy , 1997 .

[11]  H. Hricak,et al.  Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. , 1996, International journal of radiation oncology, biology, physics.

[12]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[13]  P. Unger,et al.  Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma , 1996, Cancer.

[14]  J. Oesterling,et al.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. , 1995, The Journal of urology.

[15]  G. Perry,et al.  Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. , 1995, Urology.

[16]  2210 A comparison of MRI and CT based post implant dosimetric assessment of transperineal interstitial permanent prostate brachytherapy , 1997 .

[17]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.

[18]  P. Scardino,et al.  Long-Term Results After Combined Radioactive Gold Seed Implantation and External Beam Radiotherapy for Localized Prostatic Cancer , 1988 .

[19]  J J Prete,et al.  Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[20]  M. Resnick,et al.  A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer , 1988, Springer US.

[21]  J. Cox,et al.  The significance of needle biopsy after irradiation for stage c adenocarcinoma of the prostate , 1977 .

[22]  J. Blasko,et al.  Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[23]  F M Waterman,et al.  Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. , 1996, International journal of radiation oncology, biology, physics.

[24]  D. Kuban,et al.  I–125 interstitial implantation for prostate cancer. What have we learned 10 years later? , 1989, Cancer.

[25]  B. S. Barringer RADIUM IN THE TREATMENT OF CARCINOMA OF THE BLADDER AND PROSTATE: REVIEW OF ONE YEAR'S WORK , 1917 .

[26]  W. Whitmore,et al.  Complications of 125iodine implantation and pelvic lymphadenectomy in the treatment of prostatic cancer. , 1979, The Journal of urology.

[27]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[28]  G E Hanks,et al.  Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. , 1997, International journal of radiation oncology, biology, physics.

[29]  S. Stokes,et al.  Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. , 1997, International journal of radiation oncology, biology, physics.

[30]  C. Ling Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. , 1992, International journal of radiation oncology, biology, physics.

[31]  H. Holm,et al.  Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. , 1983, The Journal of urology.

[32]  I. Kaplan,et al.  Predictors of survival after a positive post-irradiation prostate biopsy. , 1994, International journal of radiation oncology, biology, physics.

[33]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[34]  A. Shanberg,et al.  Temporary iridium‐192 implant in the management of carcinoma of the prostate , 1992, Cancer.

[35]  F. Freiha,et al.  Carcinoma of the prostate: Results of post‐irradiation biopsy , 1984, The Prostate.

[36]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[37]  M. Zelefsky,et al.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.

[38]  J. Blasko,et al.  A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems. , 1997, International journal of radiation oncology, biology, physics.

[39]  M A Moerland,et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[40]  P. Roberson,et al.  Source placement error for permanent implant of the prostate. , 1997, Medical physics.